Dr. Guenot brings nearly 20 years of experience in pharmaceutical research, venture capital and corporate and business development.

Prior to launching Guenot, LLC, Dr. Guenot was Vice President of Corporate & Business Development at PDL BioPharma, where she led licensing, mergers and acquisitions and alliance management for PDL’s R&D and commercial product portfolios.  The Biogen Idec-PDL strategic collaboration, was structured and negotiated by Dr. Guenot, and included 50:50 co-development and co-commercialization of three Phase 2 cancer and autoimmune disease drug candidates, a $100 M equity investment in PDL and a therapeutic candidate with indications split between Biogen-Idec/PDL and Hoffmann-La Roche. Later, certain rights were spun-out of the collaboration into an early stage private biotechnology company.  Dr. Guenot also built and ran centralized Contract Management and managed contract rights and obligations.  She has portfolio, project and alliance management experience in the areas of oncology, cardiovascular diseases, autoimmune diseases and ophthalmic diseases. 

Prior to PDL, during her tenure with Atlas Venture, she invested in early stage life science companies and managed venture capital investments at the Board of Directors level.  Dr. Guenot worked with CEOs, founders, other investors and advisors to build young companies:  recruiting management and board of directors, identifying and evaluating mergers & acquisitions and licensing opportunities, and developing company strategy and positioning.  She evaluated and built the business case for investments and executed legal transactions.

Dr. Guenot began her career as a scientist in preclinical R&D at Hoffmann-La Roche, discovering and developing drugs for metabolic diseases, inflammation, autoimmune diseases and oncology. 


Education
Ph.D., University of California, San Francisco (UCSF)
MBA, The Wharton School, University of Pennsylvania

Awards PDL-Biogen Idec Alliance
Innovative Bio-Partnering Awards, Biotech-Biotech Category Winner (BioBusiness Network, 2005)
Deal of Distinction (Licensing Executives Society, 2006)